[1]
|
Robert, C. (2020) A Decade of Immune-Checkpoint Inhibitors in Cancer Therapy. Nature Communications, 11, Article No. 3801. https://doi.org/10.1038/s41467-020-17670-y
|
[2]
|
Daassi, D., Mahoney, K.M. and Freeman, G.J. (2020) The Importance of Exosomal PDL1 in Tumour Immune Evasion. Nature Reviews Immunology, 20, 209-215. https://doi.org/10.1038/s41577-019-0264-y
|
[3]
|
Gao, Y., Nihira, N.T., Bu, X., Chu, C., Zhang, J., Kolodziejczyk, A., et al. (2020) Acetylation-Dependent Regulation of PD-L1 Nuclear Translocation Dictates the Efficacy of Anti-PD-1 Immunotherapy. Nature Cell Biology, 22, 1064-1075.
https://doi.org/10.1038/s41556-020-0562-4
|
[4]
|
Kuzume, A., Chi, S., Yamauchi, N. and Minami, Y. (2020) Im-mune-Checkpoint Blockade Therapy in Lymphoma. International Journal of Molecular Sciences, 21, Article No. 5456. https://doi.org/10.3390/ijms21155456
|
[5]
|
Pan, C., Yang, H., Lu, Y., Hu, S., Wu, Y., He, Q., et al. (2021) Recent Advance of Peptide-Based Molecules and Nonpeptidic Small-Molecules Modulating PD-1/PD-L1 Protein-Protein Inter-action or Targeting PD-L1 Protein Degradation. European Journal of Medicinal Chemistry, 213, Article ID: 113170.
https://doi.org/10.1016/j.ejmech.2021.113170
|
[6]
|
Zhu, H., Du, C., Yuan, M., et al. (2020) PD-1/PD-L1 Counter-attack Alliance: Multiple Strategies for Treating Triple-Negative Breast Cancer. Drug Discovery Today, 25, 1762-1771. https://doi.org/10.1016/j.drudis.2020.07.006
|
[7]
|
Mannino, M.H., Zhu, Z., Xiao, H., et al. (2015) The Paradoxical Role of IL-10 in Immunity and Cancer. Cancer Letters, 367, 103-107. https://doi.org/10.1016/j.canlet.2015.07.009
|
[8]
|
Zhu, Y., Zhu, X., Tang, C., et al. (2021) Progress and Challenges of Immunotherapy in Triple-Negative Breast Cancer. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1876, Article ID: 188593.
https://doi.org/10.1016/j.bbcan.2021.188593
|
[9]
|
Lotfinejad, P., Kazemi, T., Safaei, S., et al. (2021) PD-L1 Si-lencing Inhibits Triple-Negative Breast Cancer Development and Upregulates T-Cell-Induced Pro-Inflammatory Cyto-kines. Biomedical and Pharmacology, 138, Article ID: 111436. https://doi.org/10.1016/j.biopha.2021.111436
|
[10]
|
李莹莹, 董丽儒, 李宇阳, 等. PD-1/PD-L1在非特殊型浸润性乳腺癌中的表达及意义[J]. 广东医学, 2018, 39(11): 1690-1693.
|
[11]
|
Cimino-Mathews, A., Thompson, E., Taube, J.M., et al. (2016) PD-L1 (B7-H1) Expression and the Immune Tumor Microenvironment in Primary and Metastatic Breast Carcinomas. Human Pathology, 47, 52-63.
https://doi.org/10.1016/j.humpath.2015.09.003
|
[12]
|
Carter, J.M., et al. (2020) Frequency, Characteristics and Prognostic Factors of PD-L1+ Triple Negative Breast Cancer Using the PD-L1 SP142 Companion Assay. Cancer Re-search, 80, PD1-08.
https://doi.org/10.1158/1538-7445.SABCS19-PD1-08
|
[13]
|
Li, X., Li, M., Lian, Z., et al. (2016) Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis. Targeted On-cology, 11, 753-761. https://doi.org/10.1007/s11523-016-0451-8
|
[14]
|
赵婷婷, 张清媛. PD-1/PD-L1介导的肿瘤免疫逃逸在肿瘤微环境中的研究进展[J]. 现代肿瘤医学, 2021, 29(3): 520-523.
|
[15]
|
程敏. 程序性死亡受体-1/配体-1与p53在乳腺癌中的表达及相关性分析[D]: [硕士学位论文]. 郑州: 郑州大学, 2019.
|
[16]
|
Chen, S., Zhang, Z., Zheng, X., Tao, H., Zhang, S., Ma, J., et al. (2021) Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 11, Article ID: 562315.
https://doi.org/10.3389/fonc.2021.562315
|
[17]
|
巩海燕, 王慧, 邓晶, 等. 不同Luminal型乳腺癌超声造影特征分析[J]. 实用临床医药杂志, 2021, 25(13): 19-23.
|
[18]
|
Hong, R. and Xu, B. (2022) Breast Cancer: An Up-to-Date Review and Future Perspectives. Cancer Communications (London), 42, 913-936. https://doi.org/10.1002/cac2.12358
|
[19]
|
申梦佳, 陈杰, 卢训西, 等. 计算机定量辅助在乳腺癌ER、PR表达判读一致性中的应用[J]. 临床与实验病理学杂志, 2023, 39(5): 551-555.
|
[20]
|
Stanton, S.E., Adams, S. and Disis, M.L. (2016) Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Sys-tematic Review. JAMA Oncology, 2, 1354-1360.
https://doi.org/10.1001/jamaoncol.2016.1061
|
[21]
|
Wang, C., Zhu, H., Zhou, Y., et al. (2017) Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis. The Breast Journal, 23, 436-443. https://doi.org/10.1111/tbj.12753
|
[22]
|
王姗. PD-L1、Foxp3和TOPK在乳腺癌中的表达、作用以及临床意义[D]: [硕士学位论文]. 武汉: 华中科技大学, 2018.
|
[23]
|
刘斌亮, 谢宁, 欧阳取长. 早期HR阳性/HER2阳性乳腺癌的治疗选择与思考[J]. 中国临床新医学, 2022, 15(6): 482-487.
|
[24]
|
张佳琪. 错配修复缺陷、PD-1和PD-L1在乳腺癌组织中的表达及相关性研究[D]: [硕士学位论文]. 太原: 山西医科大学, 2021.
|
[25]
|
Chao, J., Fuchs, C.S., Shitara, K., Tabernero, J., Muro, K., Van Cutsem, E., et al. (2021) Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncology, 7, 895-902.
https://doi.org/10.1001/jamaoncol.2021.0275
|
[26]
|
黄婉莹, 杨向红. 三阴性乳腺癌中PD-1、PD-L1的表达与肿瘤浸润性淋巴细胞及临床病理指标的相关性[J]. 现代肿瘤医学, 2022, 30(12): 2181-2185.
|
[27]
|
Zhou, T., Xu, D., Tang, B., et al. (2018) Expression of Programmed Death Ligand-1 and Programmed Death-1 in Samples of Invasive Ductal Carcinoma of the Breast and Its Correlation with Prognosis. Anticancer Drugs, 29, 904-910. https://doi.org/10.1097/CAD.0000000000000683
|
[28]
|
杨林. SBEM与PD-L1在三阴型乳腺癌中的表达及临床意义[D]: [硕士学位论文]. 承德: 承德医学院, 2022.
|
[29]
|
张茂山. 乳腺癌分子分型与超声多模态诊断技术中的图像特征相关性研究[D]: [硕士学位论文]. 张家口: 河北北方学院, 2019.
|
[30]
|
Zhu, X., Ying, J., Wang, F., et al. (2014) Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Status in Invasive Breast Cancer: A 3,198 Cases Study at National Cancer Center, China. Breast Cancer Research and Treatment, 147, 551-555. https://doi.org/10.1007/s10549-014-3136-y
|
[31]
|
Lee, Y.J., Kim, S.H., Kang, B.J., et al. (2019) Con-trast-Enhanced Ultrasound for Early Prediction of Response of Breast Cancer to Neoadjuvant Chemotherapy. Ultraschall in der Medizin, 40, 194-204.
https://doi.org/10.1055/a-0637-1601
|
[32]
|
Thangarajah, F., Enninga, I., Malter, W., et al. (2017) A Retrospective Analysis of Ki-67 Index and Its Prognostic Significance in over 800 Primary Breast Cancer Cases. Anticancer Research, 37, 1957-1964.
https://doi.org/10.21873/anticanres.11536
|
[33]
|
陈军, 李庆荣, 刘宁, 等. 基于CESM影像与病理指标预测乳腺癌HER-2和Ki-67表达的价值[J]. 放射学实践, 2023, 38(11): 1409-1416.
|
[34]
|
董吉, 吴鹏西, 周锋盛, 等. 不同分子分型乳腺癌的超声造影特征临床分析[J]. 医学影像学杂志, 2022, 32(3): 441-444.
|
[35]
|
廖高庆, 马明霞. 不同分子分型女性乳腺癌超声特征分析[J]. 影像研究与医学应用, 2023, 7(11): 54-56, 60.
https://doi.org/10.3969/j.issn.2096-3807.2023.11.018
|
[36]
|
高凌, 缪绿妍, 费亚军. 多普勒超声成像与非特殊型浸润性乳腺癌病理分级及ER、PR、P53、HER-2的关系[J]. 诊断病理学杂志, 2023, 30(5): 459-463.
|
[37]
|
赵亮, 丁琼, 冷晓玲. 高频超声及超声造影在诊断乳腺癌不同分子分型中的应用研究[J]. 新疆医科大学学报, 2020, 43(10): 1352-1356.
|
[38]
|
刁金玲. 乳腺癌超声及超声造影特征与PD-1/PD-L1阳性表达相关性分析[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2022.
|